MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
68.57
+1.49 (2.22%)
Aug 14, 2026, 4:00 PM EDT - Market closed

MBX Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Income
-117.92-98.06-68.19-35.31-25.16
Net Income
-104.29-86.97-61.92-32.56-26.14
Earnings Per Share
-2.41-2.38-5.82-31.96-39.18
EPS Growth
-----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
418.58373.71262.1580.6842.46
Total Debt
3.340.60.170.320.46
Net Cash (Debt)
415.24373.11261.9880.3542
Net Cash Growth
85.16%42.42%226.04%91.31%-
Net Cash Per Share
9.5810.2224.6278.8762.97

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-82.67-79.95-54.68-31.98-23.12
Capital Expenditures
-2.53-1.93-0.87-0.13-0.44
Free Cash Flow
-85.2-81.88-55.56-32.11-23.56
Free Cash Flow Growth
-----

Valuation

Selected indicators aren't available for this stock.